Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia

J Pediatr Hematol Oncol. 2012 Jan;34(1):e17-21. doi: 10.1097/MPH.0b013e31820fee1d.

Abstract

Cytarabine (1000 mg/m/d intravenous for 5 d) and clofarabine (40 mg/m/d intravenous for 5 d) were given every 28 days to 9 children with relapsed acute myeloid leukemia at our institution. Among 19 courses, there were 18 infectious episodes. Median hospitalization time was 13 days (7.7 to 30.5 d) per cycle. Hepatobiliary abnormalities included alanine aminotransferase/aspartate aminotransferase elevation and hyperbilirubinemia. Four patients achieved complete remission (one after an earlier allogeneic Haematopoietic Progenitor Cell Transplant). Four patients are alive disease free. In summary, a proportion of children responded and was able to receive allogeneic Haematopoietic Progenitor Cell Transplant. Side effects were tolerable, although hospitalization time was prolonged.

MeSH terms

  • Adenine Nucleotides / administration & dosage
  • Adenine Nucleotides / adverse effects
  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Arabinonucleosides / administration & dosage
  • Arabinonucleosides / adverse effects
  • Child
  • Child, Preschool
  • Clofarabine
  • Cytarabine / administration & dosage
  • Cytarabine / adverse effects
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Infant
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Recurrence
  • Retrospective Studies
  • Transplantation, Homologous

Substances

  • Adenine Nucleotides
  • Arabinonucleosides
  • Cytarabine
  • Clofarabine